Business

Vertex’s cystic fibrosis treatment wins EU regulator’s backing

Vertex Pharmaceuticals Inc.’s Kalydeco, the first medicine to attack the underlying cause of cystic fibrosis, won the backing of the European Union’s drug regulator.

Kalydeco should be approved by the European Commission for use against a rare form of cystic fibrosis in patients ages 6 and older who have a specific gene mutation, the London-based European Medicines Agency said today in a statement.

Advertisement

Vertex is based in Cambridge.

In January, the US Food and Drug Administration approved Kalydeco.

Get Business Headlines in your inbox:
The Globe's latest business headlines delivered every morning, Monday through Friday.
Thank you for signing up! Sign up for more newsletters here

Earlier this month, shares of Vertex surged more than 55 percent after the company released interim data showing an experimental drug combination dramatically improved breathing for some cystic fibrosis patients taking it in a clinical trial.

About a year ago, a Vertex drug called Incivek won FDA approval to combat the hepatitis C virus.

Vertex plans to move its headquarters to the South Boston Waterfront late in 2013. The company has more than 2,000 employees worldwide, including 1,500 in Massachusetts.

Loading comments...
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.